| Outcome Measures: |
Primary: Change in vital signs, frequency and absolute value change in heart rate, blood pressure, respiration rate relative to placebo, 1, 2, 4, 8, 12, 24, 48 hours|ECGs relative to placebo, frequency of clinically significant changes in 12-lead ECG parameters relative to placebo, 1, 2, 4, 8, 12, 24, 48 hours|Changes in clinical lab results, Changes in clinical chemistry, hematology, urinalysis results relative to placebo, 24 hours|lung function tests, Measure changes in FEV, FVC, FEF 25-75%, PEFR relative to placebo, 1, 3, 8, 24 hours|Adverse events relative to placebo, Frequency and severity of adverse events relative to placebo, 48 hour monitoring | Secondary: Measurement of the maximum concentration (Cmax) for study drug, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours|Measurement of the time to achieve maximum concentration (tmax) for study drug, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours|Measurement of area under the curve (AUC) for study drug, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours|Measurement of half life (t 1/2) of study drug, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours|Measurement of apparent clearance (CL/F) of the study drug, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours|Measurement of the apparent volume of distribution (V/F) of the study drug, 0, 0.25, 0.5, 0.75, 1, 1.5, 2, 3.5, 5, 6.5, 8, 9.5, 12.5 hours
|
